ClinicalTrials.gg
RecruitingNCT06469281Updated Feb 3, 2026

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

A Phase 1 interventional study of 27T51 and Cemiplimab in Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma and Fallopian Tube Cancer, sponsored by Regeneron Pharmaceuticals. Recruiting at 5 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing bevacizumab in Carcinoma, Ovarian Epithelial — 1 open to participants now, 2 under way, none of them phase 3. Bevacizumab · Carcinoma, Ovarian Epithelial.

Planned enrollment
4th of 17
90 · median 40
Started
2024
the only one that year
Phase 1
4 of 17
1 open now
Registered
17th of 17
by date

Among the 17 studies testing bevacizumab in Carcinoma, Ovarian Epithelial, this one is the 4th largest by planned enrollment, is the only one that started in 2024, is one of 4 in phase 1, and was the 17th registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

1 of the 17 studies testing bevacizumab in Carcinoma, Ovarian Epithelial is open now, in 1 country.

By country, each count listing its studies:

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing bevacizumab in Carcinoma, Ovarian Epithelial, or all of them as a file.
02

Study summary

This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer.

This study has two (2) major parts:

Phase 1a Dose Escalation and Phase 1b Dose Expansion. The aim of the dose escalation part will be to test the safety of 27T51 in a small number of participants to find the highest dose given to humans without unacceptable side effects. The aim of the dose expansion part will be to test 27T51 at the established dose level(s) from the dose escalation part and may include other medications given in combination with 27T51.

Information collected from this study will help researchers understand more fully whether this immune cell therapy, also known as CAR T cell therapy, can be safely used to treat solid tumors such as ovarian cancer.

Read the detailed description

Former Sponsor 2seventy bio

03

Conditions studied

  • Epithelial Ovarian Cancer
  • Primary Peritoneal Carcinoma
  • Fallopian Tube Cancer

Keywords

  • Ovarian Cancer
  • CAR T
  • Peritoneal
  • Fallopian Tube
  • MUC16
  • Immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. (ECOG) performance status ≤ 1
  2. Histological diagnosis of epithelial ovarian, primary peritoneal, or fallopian tube cancer according to World of Health Organization (WHO) 2020 classification
  3. Recurrent or epithelial ovarian, primary peritoneal, or fallopian tube cancer, as described in the protocol
  4. Serum cancer antigen (CA) 125 ≥ 2 × (ULN) as assessed at the local lab by a 510(k) cleared test at screening
  5. Participants must have at least 1 measurable tumor lesion as defined by the (RECIST) 1.1.
  6. Expected survival ≥ 3 months

Key Exclusion Criteria:

  1. Inadequate cardiovascular, renal and hepatic function, as described in the protocol
  2. Absolute lymphocyte count (ALC) \< 100 cells/μL at time of leukapheresis
  3. History of Grade ≥ 2 hemorrhage within 30 days, or inadequate coagulation parameters, as described in the protocol
  4. Known history or presence of central nervous system (CNS) pathology, as described in the protocol
  5. Ongoing or recent (within 2 years) evidence of significant disease that required treatment with systemic treatments, which may suggest risk for immune related adverse events (AEs)
  6. Treatment with any cellular or gene therapy

Note: Other protocol-defined Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    27T51 monotherapy

    Other: 27T51

  • Experimental
    Dose Expansion - Arm A

    27T51 monotherapy

    Other: 27T51

  • Experimental
    Dose Expansion - Arm B

    27T51+Cemiplimab

    Other: 27T51 · Drug: Cemiplimab

  • Experimental
    Dose Expansion - Arm C

    27T51+Cemiplimab+Bevacizumab

    Other: 27T51 · Drug: Cemiplimab · Drug: Bevacizumab

Interventions

  • Other27T51

    Intravenous (IV) infusion

  • IV infusion

    Also known as: Libtayo, REGN2810

  • IV Infusion

    Also known as: Avastin, Mvasi, Vegzelma, Zirabe

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events (TEAEs)

    Part 1a

    Time frame: Up to 18 months

  2. Incidence of adverse events of special interest (AESIs)

    Part 1a

    Time frame: Up to 18 months

  3. Incidence of adverse events of dose limiting toxicities (DLTs)

    Part 1a

    Time frame: Up to 18 months

  4. Manufacturing feasibility of 27T51

    Phase 1a/1b Determination of the feasibility of manufacturing 27T51 is measured by the percent of leukapheresis products collected that are able to be manufactured and released for infusion.

    Time frame: Up to 3 years

  5. Overall response rate (ORR) as assessed by the investigator

    Phase 1b

    Time frame: Up to 48 months

Secondary outcomes

  1. ORR as assessed by the investigator

    Phase 1a

    Time frame: Up to 48 months

  2. Duration of response (DoR)

    Phase 1a/1b

    Time frame: Up to 48 months

  3. Disease control rate (DCR)

    Phase 1a/1b

    Time frame: Up to 48 months

  4. Incidence of TEAEs

    Phase 1b

    Time frame: Up to 48 months

  5. Incidence of AESIs

    Phase 1b

    Time frame: Up to 48 months

  6. Incidence of DLTs

    Phase 1b - Arms B and C

    Time frame: Up to 48 months

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for May 2030, 69 months after the start.

Of 55 phase 1 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 81. This study's planned 69 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2024
First posted
Jun 21, 2024
StartActual
Aug 6, 2024
Primary completionEst.
May 27, 2030
CompletionEst.
May 27, 2030
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06469281
Responsible party
Sponsor
First posted
Jun 21, 2024
Start date
Aug 6, 2024
Primary completion
May 27, 2030 (estimated)
Completion
May 27, 2030 (estimated)
Last update
Feb 3, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cemiplimab · Bevacizumab

Start the discussion